414 related articles for article (PubMed ID: 26362059)
1. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
3. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
[TBL] [Abstract][Full Text] [Related]
4. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
6. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
7. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
Felder S; Jann H; Arsenic R; Denecke T; Prasad V; Knappe-Drzikova B; Maasberg S; Wiedenmann B; Pavel M; Pascher A; Pape UF
Endocr Relat Cancer; 2019 Sep; 26(9):751-763. PubMed ID: 31272081
[TBL] [Abstract][Full Text] [Related]
8. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
Karakuş E; Helvacı A; Ekinci O; Dursun A
Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
[TBL] [Abstract][Full Text] [Related]
9. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
10. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
[TBL] [Abstract][Full Text] [Related]
11. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
12. Recent classifications systems for gastroenteropancreatic neuroendocrine tumors A single-center experience.
Yagmur Y; Söğutcü N; Gümüş S
Ann Ital Chir; 2020; 91():598-604. PubMed ID: 32989209
[TBL] [Abstract][Full Text] [Related]
13. Pathology - grading and staging of GEP-NETs.
Capelli P; Fassan M; Scarpa A
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
[TBL] [Abstract][Full Text] [Related]
14. Recommended parameters for pathology reporting of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Malays J Pathol; 2018 Apr; 40(1):79-82. PubMed ID: 29704389
[TBL] [Abstract][Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
[TBL] [Abstract][Full Text] [Related]
16. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
[TBL] [Abstract][Full Text] [Related]
17. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
18. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
19. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors.
Hauck L; Bitzer M; Malek N; Plentz RR
Scand J Gastroenterol; 2016 Jan; 51(1):55-9. PubMed ID: 26137871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
